Key Highlights

  • AGIO shares trading down 14.61% today to $31.79
  • FDA goal date for mitapivat in sickle cell disease is November 1, 2026
  • Cash and marketable securities were about $1 billion at the end of June
  • Second-quarter mitapivat net Revenue was $44.7 million
  • Second-quarter net loss was $100.7 million, versus $112 million a year earlier

Shares Slide Two Days Before the Mitapivat Sickle Cell Decision Date

Agios Pharmaceuticals (NASDAQ:AGIO) shares are trading down 14.61% today at $31.79. No company-specific announcement was identified for the decline, which comes just ahead of a major regulatory milestone.

The FDA accepted Agios' supplemental application for mitapivat in sickle cell disease under Priority Review for accelerated approval, with a goal date of November 1, 2026. Agios develops therapies for rare diseases built around pyruvate kinase activators, and mitapivat is already approved for pyruvate kinase deficiency and thalassemia.

The sickle cell filing is a significant event for a company that has relied on one core franchise. Trading ahead of a binary regulatory outcome can be volatile in either direction.

Tebapivat Programs Were Discontinued Earlier in the Year

Agios stopped development of tebapivat in lower-risk myelodysplastic syndromes on June 1 after a mid-stage study did not meet its predefined efficacy threshold for durable transfusion independence. The drug showed biological activity and was generally well tolerated.

On July 21, the company reported Phase 2 sickle cell results for tebapivat in 59 participants. Hemoglobin response was 43.8% at 2.5 mg, 47.1% at 5.0 mg and 29.4% at 7.5 mg, against 33.3% for placebo. Agios said the trial did not show the differentiation needed to continue, and it shifted its focus to mitapivat.

Both programs were early efforts to extend the company's pyruvate kinase approach into new conditions. Neither effort advanced beyond mid-stage testing.

Second-Quarter Revenue Growth and a Cash Cushion of About $1 Billion

For the second quarter, mitapivat net revenue was $44.7 million, including $40.9 million in the United States and $3.8 million elsewhere. About $5 million of that was a one-time benefit tied to thalassemia stocking. Net loss narrowed to $100.7 million from $112 million a year earlier.

Agios held roughly $1 billion in cash and marketable securities at the end of June. It maintained 2026 U.S. pyruvate kinase deficiency revenue guidance of $45 million to $50 million, with operating expenses roughly flat versus 2025 excluding a $25 million upfront payment for cevidoplenib.

Management said it targets about 25,000 actively treated or eligible sickle cell patients initially, has dosed the first patient in the Phase 3 REIGNITE confirmatory trial, and does not expect sickle cell sales to contribute materially to 2026 revenue.

Agios also noted that gross-to-net adjustments were expected in a range of 10% to 20% for 2026, which affects how much of list price converts to reported revenue.

The November 1 FDA Goal Date Is the Next Dated Catalyst for AGIO

With no disclosed trigger for today's drop, the regulatory outcome on mitapivat in sickle cell disease is the nearest known event. November 1 falls on a Sunday, so the timing of any announcement may extend into the following week.

Investors will also look for third-quarter results, which have not been confirmed in the sources reviewed, and any update on a launch plan or Brand name.

Agios previously said it was prepared to launch with or without a risk evaluation program, leaving the label terms as a key detail in any decision.